ViiV Healthcare announces FDA priority review designation for dolutegravir
- Details
- Category: GlaxoSmithKline
ViiV Healthcare announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection, in combination with other antiretroviral agents, in adults and adolescents.
Accelerating focus on the patient
- Details
- Category: UCB
With its "crossover year" delivered in 2012 and UCB's new core medicines now driving company growth, UCB's transformation into a biopharma company is complete. UCB is now entering an important new phase of revenue growth with no major patent expiry expected until the end of the decade.
Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plc
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced it has entered into a three-year collaboration agreement with Reckitt Benckiser Group plc (LSE: RBL) for several of its over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil.
Sanofi delivers solid 2012 results despite patent expirations
- Details
- Category: Sanofi
In the fourth quarter of 2012, Sanofi (EURONEXT: SAN and NYSE: SNY) generated sales of €8,526 million, an increase of 0.2% on a reported basis. Exchange rate movements had a positive effect of 1.9 percentage points primarily reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Chinese Yuan, Mexican Peso, Australian dollar and British Pound against the Euro.
Novo Nordisk increased operating profit by 32% in 2012
- Details
- Category: Novo Nordisk
Novo Nordisk has announced that sales increased by 18% to 78.0 billion in Danish kroner and by 12% in local currencies. Reported operating profit increased by 32% to DKK 29.5 billion including a 1.7 percentage points improvement in the gross margin. Measured in local currencies, operating profit increased by 20%.
Roche delivers strong 2012 results
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) delivered a strong performance in 2012, with Group sales rising 4% to 45.5 billion Swiss francs due to growing demand for its cancer medicines and increased sales of diagnostic tests to clinical laboratories. This solid sales growth, along with productivity improvements, resulted in a double-digit increase in core operating profit and core earnings per share (EPS), as well as improved profitability.
AstraZeneca fourth quarter and full year results 2012
- Details
- Category: AstraZeneca
AstraZeneca's revenue in the fourth quarter was down 15 percent at constant exchange rates (CER) and declined by 16 percent on an actual basis as a result of the negative impact of exchange rate movements. Loss of exclusivity on several key brands accounted for the revenue decline.
More Pharma News ...
- GSK response to news article in The Guardian on UK legal proceedings related to Avandia
- Bristol-Myers Squibb reports fourth quarter financial results
- Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
- Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
- Takeda establishes new trading company and reinforces business structure in China
- Novartis makes progress in the fight to eliminate leprosy worldwide
- FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC